-
Founded in:
2000-12-07 -
Country:
China -
Address:
Green Industrial Park, Jiedong Economic Development Zone, Jieyang City -
Tax NO.:
9144520372599310X7 -
Registered Funds:
20 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefonicid sodium |
This product is a second-generation cephalosporin for intravenous or intramuscular injection. This product has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.
More
This product is a second-generation cephalosporin for intravenous or intramuscular injection. This product has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and Group B Streptococcus, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Streptococcus faecalis, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, Group B Streptococcus and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive. |
61270-78-8 | 15 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefpiramide acid |
|
70797-11-4 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefpiramide acid |
|
70797-11-4 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefpiramide acid |
|
70797-11-4 | 9 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Cefteram pivoxil |
It blocks the synthesis of bacterial cell walls and has strong binding to 3, 1A, 1Bs in penicillin binding protein (PBP). It has antibacterial effects on both Gram-positive and Gram-negative bacteria, especially on Streptococcus, Pneumococcus, Escherichia coli, Klebsiella, Neisseria gonorrhoeae, Haemophilus influenzae, anaerobic bacteria, Streptococcus pyogenes, etc. It also has good antibacterial effects on Serratia, indole-positive Proteus, Enterobacter, Citrobacter, etc. It is effective against strains that produce β-lactamase. No reports of carcinogenicity and teratogenicity have been found.
More
It blocks the synthesis of bacterial cell walls and has strong binding to 3, 1A, 1Bs in penicillin binding protein (PBP). It has antibacterial effects on both Gram-positive and Gram-negative bacteria, especially on Streptococcus, Pneumococcus, Escherichia coli, Klebsiella, Neisseria gonorrhoeae, Haemophilus influenzae, anaerobic bacteria, Streptococcus pyogenes, etc. It also has good antibacterial effects on Serratia, indole-positive Proteus, Enterobacter, Citrobacter, etc. It is effective against strains that produce β-lactamase. No reports of carcinogenicity and teratogenicity have been found. |
82547-81-7 | 7 |